Although our findings regarding rate reductions in composite OAC with semaglutide should be interpreted with caution due to the lack of association in the sensitivity analysis (exclusion of individuals that developed cancer within 6 months), our findings of reductions in OAC, colorectal, liver and pancreatic cancer are broadly consistent with the previous literature investigating the effect of GLP‐1 RAs on cancer incidence. This evidence concerns the gene GLP1R and pancreatic neoplasm.